Breaking News

Lilly to Acquire Novartis Animal Health

April 22, 2014

Creates second-largest animal health company

Eli Lilly and Co. has entered an agreement to acquire Novartis Animal Health for approximately $5.4 billion in cash. The acquisition expands Lilly's animal health business, Elanco, and creates the second-largest animal health company in terms of global revenue.
 
Novartis Animal Health has a presence in 40 countries and had approximately $1.1 billion in revenues in 2013. Lilly will acquire its nine manufacturing sites, six dedicated R&D facilities, a global commercial infrastructure with a portfolio of approximately 600 products, a pipeline of more than 40 projects in development, and a team of more than 3,000 employees.
 
The transaction is expected to close by 1Q15, subject to customary closing conditions.

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016